For example, diabetes seems to directly hinder the effects of mammalian target of rapamycin (mTOR) inhibition on vascular smooth muscle cell (VSMC) proliferation, mandating at least a tenfold higher drug concentration in order to achieve a similar level of inhibition. Here, MTOR is linked to diabetes mellitus.